5-aza-2′,2′-Difluroro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of Cancer

Richard Daifuku 1*, Zhenbo Hu 2 and Yogen Saunthararajah 3

1 Epigenetics Pharma, 9270 SE 36th Pl, Mercer Island, WA 98040, USA
2 Department of Hematology, Affiliated Hospital of Weifang Medical University, Weifang 261000, China; zhenbohux@163.com
3 Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center Cleveland, Cleveland, OH 44011, USA; saunthy@ccf.org
* Correspondence: rdaifuku@yahoo.com

Received: 25 November 2016; Accepted: 16 July 2017; Published: 20 July 2017

Abstract: Tumor suppressor genes can be silenced genetically as well as epigenetically. One approach to reversing epigenetic suppression of tumor suppressor genes is to inhibit DNA methyl transferase. 5-aza-2′,2′-difluroro deoxycytidine (NUC013) is a novel DNA methyl transferase and ribonucleotide reductase inhibitor that is a more potent inhibitor of growth than decitabine in the NCI 60 cancer cell line panel. NUC013 is more active than decitabine against p53-null/mutant cancer cell lines (p = 0.027) but is even more so against p53 wild-type (WT) cell lines (p = 0.0025). The maximum tolerated dose in mice of NUC013 is greater than 120 mg/kg administered intravenously for three consecutive days a week for three weeks. With this regimen and a dose of 20 mg/kg in a human leukemia HL-60 (p53-null) NCr-nu/nu mouse xenograft model (n = 10/group), NUC013 demonstrated a survival benefit (saline median survival (MS) = 26.5 days, NUC013 MS = 32 days and hazard ratio (HR) = 0.26 (p = 0.032)). In a colon cancer LoVo (TP53 WT) xenograft, mice treated with decitabine at 5 mg/kg had worse survival than saline controls (decitabine MS = 31 days, saline MS > 60 days and HR = 26.89 (p < 0.0001)). At a dose of 20 mg/kg NUC013, mean tumor volume in the LoVo xenografts was lower than controls by 50.9% and at 40 mg/kg by 53.7% (both p < 0.0001).

Keywords: DNA methyl transferase; ribonucleotide reductase; nucleoside; NUC013; decitabine; 5-azacytidine; gemcitabine; p53

1. Introduction

An aberrant gain of DNA methylation at the promoter CpG islands and enhancer regions of critical tumor suppressors is observed in most cancers and leads to the inactivation of the expression of genes that suppress tumorigenesis [1]. The genes involved include those that suppress apoptosis, differentiation, metastasis and angiogenesis, those that repair DNA and those that express tumor-associated antigens [2].

5-aza-2′,2′-difluroro deoxycytidine (NUC013) is a novel nucleoside analog designed to be a DNA methyl transferase inhibitor (DNMTI) and ribonucleotide reductase inhibitor (RNRI). NUC013 consists of the base of 5-azacytidine (Vidaza®, Celgene, Summit, NJ, USA) or 5-aza-2′-deoxycytidine, also known as decitabine, (Dacogen®, Otsuka America Pharmaceutical, Rockville, MD, USA) conjugated with the sugar moiety of gemcitabine (Gemzar®, Eli Lilly, Indianapolis, IN, USA) (see Figure 1).
Both 5-azacytidine and decitabine are approved in the United States for the treatment of myelodysplastic syndrome (MDS). More recently, decitabine has been approved in the European Union for the treatment of acute myeloid leukemia [3]. These nucleosides were first synthesized in 1964 [4,5]. The lack of approved novel molecules in the interim attests to the difficulty in designing safe and effective molecules of this class.

To be active as a DNMTI, 5-azacytidine must first be reduced in vivo to the deoxy-analog, decitabine. Decitabine must then be phosphorylated to decitabine triphosphate and incorporated in DNA before inhibiting DNA methylation [6]. Both drugs produce remissions or clinical improvements in more than half of the treated patients with MDS. Optimization of therapy has included (1) reducing the dose to favor hypomethylation over cytotoxicity; (2) prolonging administration schedules and (3) increasing dose intensity without reaching cytotoxicity. Considering that both have the common side effect of myelosuppression that limits dosing and duration of treatment, it is clear that better inhibitors of DNA methylation are needed for clinical use, particularly ones that have less cytotoxicity and more activity against solid tumors [7,8]. Data from the two currently approved drugs suggest that myeloid malignancies are the neoplasms most sensitive to inhibitors of DNA methylation; however, there is no known reason why solid tumors should not respond as well [9,10].

Gemcitabine is approved as a first line treatment for pancreatic cancer and as combination therapy for other solid tumors. It is an inhibitor of DNA synthesis and, most relevant to NUC013, gemcitabine diphosphate inhibits RNR. Inhibition of RNR causes a reduction in the concentrations of deoxynucleotides, including deoxycytidine triphosphate (dCTP). As gemcitabine triphosphate competes with dCTP for incorporation into DNA, the reduction in the intracellular concentration of dCTP enhances the incorporation of gemcitabine triphosphate into DNA (a mechanism that has been described as self-potentiation) [11].

2. Results

2.1. NUC013 DNMT Inhibition

NUC013 and 5-azacytidine were first tested for growth inhibition against human colon cancer cell line HCT-116 (TP53 WT), which is also part of NCI 60 cell line panel. The concentration of drug that inhibited 50% of cell growth (GI50) for 5-azacytine was 0.62 µM versus 4.54 µM for NUC013. In HCT-116, NUC013 at 1 µM achieves 53.4% inhibition of total DNMT in a colorimetric assay compared to 19.2% for 5-azacytidine (means of 3 experiments, p = 0.060, paired t-test, two-tailed). At 10 µM, NUC013 inhibition of total DMNT was 48.5% versus 48.6% for 5-azacytidine.

These results were confirmed and extended in human leukemia Kasumi-1 (TP53 R248Q mutant) and THP-1 (TP53 null) cell lines. In these cell lines, NUC013 demonstrated DNMT1 inhibition by western blot comparable to decitabine at 0.1 and 0.2 µM in THP-1 cells, though DNMT1 inhibition in the same concentration range is weaker than decitabine in Kasumi-1 cells (See Figure 2A).
In these same cell lines, NUC013 demonstrated apoptosis after 24 h starting at a concentration of 0.25 μM in Kasumi-1 and 0.2 μM in THP-1 (Figure 2B), compared to 0.75–1 μM for decitabine (data not shown). Similar to decitabine, NUC013 resulted in morphologic changes suggestive of cell differentiation 6 days following exposure to study drug (Figure 2C).
2.2. NUC013 RNR Inhibition

RNR inhibition by NUC013 was evaluated by exposing HeLa cells to drug and then determining by high-performance liquid chromatography (HPLC) whether deoxynucleotide synthesis was inhibited when compared to negative control cells. Gemcitabine was used as a positive control.

Table 1 shows that neither gemcitabine nor NUC013 affected concentrations of ribonucleotides. However, lower concentrations of deoxyribonucleotides are noted from lysates from cells treated with gemcitabine or NUC013, in particular of dATP, dGDP and dUTP. dTDP appears to be unaffected by the presence of NUC013, while the increase in levels of dTDP with gemcitabine may be due to co-elution with gemcitabine-DP.

Table 1. Concentration of nucleotides from HeLa cell extracts comparing treatment with 50 µM gemcitabine or NUC013 vs. control, where A: adenine, G: guanine, T: thymidine, U: uridine, d: deoxy, DP: diphosphate, TP: triphosphate and AU: absorbance units.

| Nucleotide | Control, T1 | Control, T2 | Gemcitabine (50 µM) | NUC013 (50 µM) |
|------------|-------------|-------------|---------------------|----------------|
| dATP peak area, AU | 15.8 | 15.3 | 0 | 10.2 |
| dGDP peak area, AU | 11.3 | 10.3 | 7.95 | 5.6 |
| dTDP peak area, AU | 20.6 | 18.2 | 43.4 | 18.65 |
| dUTP peak area, AU | 16.8 | 35.2 | 5.3 | 8.8 |
| ADP | 14,052 | 14,188 | 15,639 | 13,845 |
| ATP | 22,163 | 17,489 | 26,296 | 21,335 |
| GTP | 2003 | 1151 | 2036 | 2006 |
| CTP | 1209 | 848 | 1297 | 1279 |
| UTP | 4011 | 4146 | 4801 | 4070 |

2.3. NUC013 Cancer Cell Line Activity

Extensive testing has been performed on the activity of NUC013 in cancer cell lines, including the NCI 60 cell line panel. The panel comprises human cancer cell lines representing nine different tissues of origin: breast, colon, central nervous system, renal, lung, melanoma, ovarian, prostate and hematogenous. These cells lines are very well characterized, and their TP53 status has been reported in the literature [12].

As of early 2007, all compounds submitted to the NCI 60 Cell Panel have been tested initially at a single dose (10 µM). Hence, it is only possible to compare activity at 10 µM; for decitabine, whether the log GI50 is $<-5.0$ M or $\geq-5.0$ M, while for NUC013 whether at 10 µM percent growth is $\geq50\%$ or <50%. Only cell lines that were tested for both compounds are presented, as the composition of the panel has undergone some minor changes with time (see Supplementary Table S1).

Using the cut-off of 10 µM, it is possible to summarize and compare the activity of decitabine and NUC013 in the NCI 60 cell line panel and determine what influence, if any, the presence of TP53 WT has on growth inhibition by decitabine or NUC013 in 2 × 2 contingency tables. As shown in Table 2, NUC013 was significantly more effective than decitabine in the NCI 60 Cell Line Panel ($p = 0.0002$).

Table 2. Allocation of cell lines of NCI 60 cell line panel treated with decitabine or NUC013 by growth inhibition at 10 µM.

| Growth Inhibition at 10 µM | Number of Cell Lines |
|---------------------------|----------------------|
|                           | Decitabine | NUC013 |
| >50%                      | 6          | 24     |
| $\leq50\%$                | 49         | 31     |

Fisher’s exact test two-tailed, $p = 0.0002$.

In Table 3, $p = 0.66$ confirmed a very high probability of a true null hypothesis, i.e., that TP53 status had no effect on decitabine GI50. In contradistinction, data in Table 4 demonstrated that for NUC013 there was a significant association ($p = 0.013$) between TP53 status and cell growth inhibition.
Another way to look at the data is that while a comparison of NUC013 efficacy versus decitabine in TP53 null/mutant cell lines was statistically significant ($p = 0.027$, Fisher’s exact test, two-tailed), results in TP53 WT cell lines reach an even more stringent level of statistical significance ($p = 0.0025$, Fisher’s exact test, two-tailed).

Table 3. Allocation of cell lines of NCI 60 cell line panel treated with decitabine by growth inhibition at 10 µM and TP53 status.

| Growth Inhibition at 10 µM | Decitabine |
|----------------------------|------------|
|                           | TP53 (Null/Mutant) | TP53 (WT) |
| >50%                      | 4          | 2         |
| ≤50%                      | 36         | 13        |

Fisher’s exact test two-tailed, $p = 0.66$.

Table 4. Allocation of cell lines in NCI 60 cell line panel treated with NUC013 by growth inhibition at 10 µM and TP53 status.

| Growth Inhibition at 10 µM | NUC013 |
|----------------------------|--------|
|                           | TP53 (Null/Mutant) | TP53 (WT) |
| >50%                      | 13      | 11        |
| ≤50%                      | 27      | 4         |

Fisher’s exact two-tailed, $p = 0.013$.

Further testing was performed in colon cancer cell lines. NUC013 was tested against decitabine in two TP53 WT colon cancer cell lines which are not part of the NCI 60 cell line panel: Ls174T and LoVo. The GI$_{50}$ was greater than 50 µM for decitabine in both cell lines, while for NUC013, the GI$_{50}$ was 1.3 µM for Ls174T and 3.0 µM for LoVo (see Supplementary Figure S1).

2.4. NUC013 Pharmacology

Pharmacokinetic experiments of intravenous injections of NUC013 in mice demonstrated a half-life of 20.1 min (see Table 5). NUC013 could not be identified at the 6 and 24 h timepoints (see Figure S2).

Table 5. Pharmacokinetic parameters of NUC013 after intravenous (IV) administration in mice. Pharmacokinetic parameters were obtained from the non-compartmental analysis of the plasma data using WinNonlin. The analytical method was not validated for NUC013 and did not use addition of tetrahydrouridine, an inhibitor of cytidine deaminase, after specimen collection and, hence, may have resulted in an underestimate of the area under the curve (AUC) and half-life.

| Animal | $t_{1/2}$ (h) | $C_0$ (ng/mL) | AUClast (h·ng/mL) | AUCInf (h·ng/mL) | AUC Extr (%) | Vss (L/kg) | CL (mL/min/kg) | MRT (h) | Last time point for AUClast (h) |
|--------|--------------|---------------|-------------------|-----------------|--------------|------------|----------------|---------|-------------------------------|
| IV-Mouse | 0.335 | 36,941 | 11,082 | 11,086 | 0.04 | 0.26 | 9.10 | 0.292 | 4 |

2.5. NUC013 Tolerability

NUC013 was tested in mice at repeat doses of up to 120 mg/kg IV for 3 consecutive days per week for 3 weeks, without evidence of weight loss or death over the time period of observation.

2.6. Xenograft Studies with NUC013

NUC013 was tested against a positive control (decitabine) and a negative control (saline) in two mouse models ($n = 10$ per group). Drugs were administered IV for 3 consecutive days a week for 3 weeks. HL-60 is a human leukemia cell line (TP53 null) that is part of the NCI 60 cell line panel and
can be grown in nude mice. LoVo is a colon cancer cell line (TP53 WT) that demonstrated good in vitro activity of NUC013.

2.7. HL-60 Xenograft Model

For HL-60, it is possible to analyze survival because the tumor is rapidly lethal. In the first study, mean tumor volume at treatment initiation was 188 mm³. At a dose of 5 mg/kg of decitabine and the equimolar dose of NUC013 to saline control, the median survival (MS) of treated groups did not significantly differ from that of saline control (Figure 3A), nor did tumor volumes (Figure 4A). It is noteworthy though that 4 out of 10 mice died or were euthanized for moribundity in the decitabine group, while none were in the NUC013 or saline groups.

![Survival proportions in HL-60 and LoVo xenografts treated with decitabine or NUC013](image)

Figure 3. Survival proportions in HL-60 and LoVo xenografts treated with decitabine or NUC013 (n = 10/group). “Survival” refers to animals that were not removed from the study by death or per protocol euthanasia. (A) Survival proportion in HL-60 xenografts. Saline control compared to decitabine (5 mg/kg) and NUC013 (5.8 mg/kg). Saline median survival (MS) = 25 days, decitabine MS = 26 days, and hazard ratio (HR) = 0.92 (p = 0.64, Log-rank test); NUC013 MS = 28.5 days and HR = 0.59 (p = 0.19, Log-rank test); (B) Survival proportion in HL-60 xenografts. Saline compared to NUC013 (20 mg/kg). Saline MS = 26.5 days, NUC013 MS = 32 days and HR = 0.26 (p = 0.032, Log-rank test); (C) Survival proportion in LoVo xenografts. Saline control compared to decitabine (5 mg/kg) and NUC013 (5.8 mg/kg). Saline MS undefined, decitabine MS = 31 days and HR of 26.89 (p < 0.0001, Log-rank test); NUC013 MS = 60 days and HR = 1.64 (p = 0.48); (D) Survival proportion in LoVo xenografts. Saline control compared to 20 mg/kg and 40 mg/kg NUC013. MS undefined.
Figure 4. Tumor volume as a function of time since tumor implant. The first data point on each graph is on the day of study drug treatment initiation. Values are ± standard deviation. (A) HL-60 comparison of NUC013 5.8 mg/kg vs. saline control; (B) HL-60 comparison of NUC013 20 mg/kg vs. saline control; (C) LoVo comparison of NUC013 5.8 mg/kg vs. saline control; (D) LoVo comparison of NUC013 20 mg/kg and 40 mg/kg vs. saline control.

In the second study, the mean tumor volume at study initiation was 33 mm$^3$ and treatment with NUC013 (20 mg/kg) significantly improved MS ($p = 0.032$) (Figure 3B). Furthermore, significant decreases in tumor volume ($p < 0.05$, Mann-Whitney U test, two-tailed) were noted on study days 18 through 28 (see Figure 4B), reaching a maximum on study days 21 and 25 (47.8% lower than saline control).

2.8. LoVo Xenograft Model

In the first study, treatment was initiated in mice when tumor reached a mean of 173 mg. The data were most striking for the presence of decitabine toxicity at a dose of 5 mg/kg (8 mice died while 2 were euthanized for ulcerated tumors) versus saline ($p < 0.0001$) (see Figure 3C). At equimolar doses of NUC013 8 days following the end of treatment (study day 27), mean tumor volume was lower by 24.3% compared to controls ($p = 0.048$, $t$-test, two-tailed) (see Figure 4C). In the second study, at a dose of 20 mg/kg of NUC013 (mean tumor volume 66 mm$^3$ at treatment initiation), the graph shows trends towards improved survival (see Figure 3D). Mean tumor volumes were significantly lower in both treated groups ($p < 0.05$, Mann-Whitney U test, two-tailed) on study days 9 through 51, compared to saline control. As with the dose of 5 mg/kg, mean tumor volume in treated mice decreased the most
compared to control mice 8 days following the end of treatment (study day 30): 50.9% in mice treated with 20 mg/kg and 53.7% when mice were treated with 40 mg/kg (both $p < 0.0001$, $t$-test, two-tailed) (see Figure 4D).

3. Discussion

In colon cancer cells (HCT-116, TP53 WT), NUC013 showed a greater than 50% total DNMT inhibition at 1 µM. NUC013 achieved this level of DNMT inhibition at a concentration that was lower than its $GI_{50}$ (4.54 µM), while such was not the case for 5-azacytidine ($GI_{50} = 0.62$ µM) where the concentration required to achieve similar levels of inhibition was greater than 1 µM but likely less than or equal to 10 µM. NUC013 was confirmed as a DNMT1 inhibitor in leukemic cell lines THP-1 and Kasumi-1.

Like all 5-azacytidines, the 5-azacytosine base of NUC013 is susceptible to hydrolysis at the 6-position of the cytosine ring (see Figure 1) with release of a formyl group (data not shown). This susceptibility to hydrolysis is intrinsic to the ability of 5-azacytidines to donate this formyl group to the active serine site of a DNMT resulting in the enzyme’s inactivation [13].

Many 2′-substituted-2′-deoxynucleotides have been shown to be a potent mechanism-based RNRI. Detailed studies on 2-fluoro, 2-chloro and 2-azido derivatives have provided the basis for a general mechanism of inhibition by these substrate analogs [14]. There are a number of approaches to determining whether a compound inhibits RNR. One approach is to synthesize a nucleoside diphosphate and then determine whether it inhibits purified RNR or p53R2 [15]. This approach would be technically very difficult with NUC013 because the diphosphate is likely to be quite unstable based on data generated with 5-azacytidine [16] and our experience synthesizing decitabine-MP. The other approach is to expose cells in tissue culture to the drug and determine whether deoxynucleotide synthesis from RNR and p53R2 is inhibited when compared to control cells. Measurement of deoxynucleotides may be done by radioimmunoassay or by HPLC. The disadvantage of a radioimmunoassay is that it can only measure a single deoxynucleotide triphosphate (dNTP) at a time and typically requires a tritiated nucleotide, but it is the preferred method for measuring dCTP [17]. On the other hand, HPLC can measure multiple nucleotides without requiring radiolabeling but has been noted to quantitate poorly dC nucleotides, possibly as an artifact of an influx of dCTP from the medium [18]. In the HPLC assay, both gemcitabine and NUC013 show lower concentrations than control of dATP, dGDP and dUTP. In this assay, inhibition of dATP and dUDP/dUTP synthesis are the hallmarks of gemcitabine inhibition of RNR [19]. dTDP levels are elevated in the case of gemcitabine or unaffected in the case of NUC013. The other approach is to expose cells in tissue culture to the drug and determine whether deoxynucleotide synthesis from RNR and p53R2 is inhibited when compared to control cells. Measurement of deoxynucleotides may be done by radioimmunoassay or by HPLC. The disadvantage of a radioimmunoassay is that it can only measure a single deoxynucleotide triphosphate (dNTP) at a time and typically requires a tritiated nucleotide, but it is the preferred method for measuring dCTP [17]. On the other hand, HPLC can measure multiple nucleotides without requiring radiolabeling but has been noted to quantitate poorly dC nucleotides, possibly as an artifact of an influx of dCTP from the medium [18]. In the HPLC assay, both gemcitabine and NUC013 show lower concentrations than control of dATP, dGDP and dUTP. In this assay, inhibition of dATP and dUDP/dUTP synthesis are the hallmarks of gemcitabine inhibition of RNR [19]. dTDP levels are elevated in the case of gemcitabine or unaffected in the case of NUC013. The increased levels in the case of gemcitabine may be related to co-elution of gemcitabine-DP and dTDP and the unchanged levels for NUC013 may be due to the existence of a salvage pathway for formation of the deoxynucleotide independent from RNR [20]. It should be noted that assessment of the relative effectiveness of the compounds as RNRI may vary depending on the cell line used for the assay and that HeLa cells are TP53 null.

The p53R2 gene encodes a small subunit of RNR and has been identified as a p53-inducible gene. While gemcitabine does not induce p53R2, it has been shown to result in its inhibition [15]. Conversely, p53R2 has been shown to be inducible by decitabine and among other activities, p53R2 provides deoxynucleotides in response to p53 activation [21]. More recently, expression of p53R2 has been associated with cancer progression and resistance to therapy [22–24]. RNR is a complex between two proteins: the large catalytic protein R1 that contains the allosteric sites and the smaller protein R2. Both proteins are transcriptionally activated during early S-phase and are present in roughly equal amounts to deliver the dNTP required for DNA replication. R2 is degraded during late mitosis and thus postmitotic quiescent cells are essentially devoid of R2 but retain some R1. In postmitotic resting cells, only p53R2 can act as the functioning small subunit of RNR because it is not degraded in mitosis. After DNA damage, p53R2 is transcriptionally activated by p53 and is translocated into the nucleus but has also been shown to be present in the cytosol [25].
Decitabine has been thought of as an S-phase specific agent [26]. However, it has recently been shown that the cell cycle dependence of decitabine is not absolute. Its secondary, epigenetic effects are replication dependent, but its primary effect, DNMT1 enzyme depletion, occurs immediately with elimination half-lives that are unrelated to the fraction of cells in S-phase. Thus, DNA repair and remodeling activity in arrested, confluent cells may be sufficient to support the primary molecular action of decitabine, while its secondary, epigenetic effects require cell cycle progression through S-phase [27]. The ability of NUC013 to inhibit DNMT at a concentration below that causing substantial cell growth arrest favors the expression of its epigenetic effects.

The inhibition of RNR by gemcitabine has been reported to lead to depletion of dCTP, a potent feedback inhibitor of deoxycytidine kinase, leading to a more efficient phosphorylation of gemcitabine. Moreover, since gemcitabine competes with dCTP, a decrease in dCTP pools increases incorporation of gemcitabine into DNA, a mechanism that has been described as self-potentiation [28]. This same mechanism of action is hypothesized to apply to NUC013 and inhibition of RNR and p53R2. Thus, NUC013 can inhibit dNTP synthesis not only during S phase but throughout the cell cycle. In contradistinction, restoration of p53 WT function by decitabine [29] and induction of p53R2 should increase the pool of dCTP, thereby decreasing the incorporation of decitabine during the resting phase, a mechanism that might be described as “self-antagonism”. This self-antagonism may be one reason for the lesser activity of decitabine when compared to NUC013.

Evidence suggests that tumor suppressor gene silencing is an early initiating event in the oncogenic process and that maintaining expression of these genes may well impede the onset of tumorigenesis and tumor progression [1]. The tumor suppressor gene TP53 is of vital importance in preventing human cancer development and progression, and is often referred to as the “guardian of the genome.” Mutations of its gene are detected in approximately 50% of all types of human cancers, and the functions and stability of the p53 protein are often abrogated via posttranslational mechanisms, such as DNA methylation, in the rest of human cancers that harbor TP53 WT. p53 is often inactivated in cancer because it can trigger cell growth arrest, apoptosis, utophagy or senescence, which are detrimental to cancer cells, and it impedes cell migration, metabolism or angiogenesis, which are favorable to cancer cell progression and metastasis [30].

NUC013 has been shown to inhibit the growth of hematogenous tumor cell lines by more than 50% at 10 µM and at least one cell line from all solid tumor tissues tested in the NCI 60 cell line panel, including breast, colon, central nervous system, renal, lung, melanoma, ovarian and prostate. While decitabine is no more effective against TP53 WT than TP53 null/mutant cell lines, NUC013 is significantly more effective (p = 0.013) against TP53 WT cell lines. This result is compatible with the experimental data generated by Nieto and others that decitabine unexpectedly induced more apoptosis in TP53 null cells than in TP53 WT cells [31–33]. As with decitabine, treatment with NUC013 has also been shown to result in morphologic changes suggesting cell differentiation and to induce apoptosis by a p53 independent mechanism at submicromolar doses. Decitabine has been shown to induce apoptosis in p53 null cell lines by generating reactive oxygen species [34].

Pharmacokinetic experiments of intravenous injections of NUC013 in mice demonstrate a half-life of 20.5 min compared to 30 min reported for decitabine [35]. Cytidine deaminase is considered to be responsible for the relatively short half-life of deoxycytidine analogs in vivo [36,37].

On a schedule of 3 consecutive daily IV doses per week for 3 weeks, NUC013 has been shown to be safer than decitabine in mice. The maximum tolerated dose (MTD) of decitabine is under 5 mg/kg while that of NUC013 is over 120 mg/kg when administered to nude mice on the same schedule, a greater than 24-fold difference. A mean GI50 is provided for decitabine in the NCI 60 cell line panel but one is not available for NUC013. However, as a result of GI50’s generated for cell lines, such as HCT-116, which were also part of the NCI 60 panel (data not shown), the mean GI50 of NUC013 can be estimated to be no better than 10-fold lower than decitabine. Hence, the therapeutic index of NUC013 may be conservatively estimated, depending on the actual MTDs, to be in the range of 100- to 150-fold better than decitabine.
In xenograft models implanted with cell lines sensitive to NUC013 and relatively resistant to decitabine, better activity was demonstrated for NUC013. In mice treated with NUC013, survival was significantly improved for a hematogenous tumor (p53 null) and tumor growth significantly inhibited for a solid tumor (p53 WT) compared to untreated mice. This suggests that in vitro activity in other cell lines, whether solid or hematogenous, p53 null or WT, may also translate to activity in vivo.

4. Materials and Methods

4.1. NUC013

NUC013 was originally synthesized at Sonus Pharmaceuticals (Bothell, WA, USA) and more recently by NuChem Therapeutics (Montreal, QC, Canada).

4.2. Total DNMT Inhibition

Total DNMT activity was measured in the colon cancer cell line HCT-116. The assay was performed using the EpiQuick™ DNA Methyltransferase Activity/Inhibition Assay Kit (Epigentek, Brooklyn, NY, USA) [38]. The HCT-116 cells were incubated with 1 µM and 10 µM concentrations of 5-acytidine or NUC013 for a period of 24 h. Assays were performed three times in triplicate.

4.3. Western Blot for DNMT1

Approximately 100 µg of cytoplasmic and nuclear protein extracts from cells, together with molecular weight markers, were subjected to SDS-PAGE on 4–12% gradient gels (Invitrogen, Carlsbad, CA, USA) followed by transfer to polyvinylidene fluoride membranes (Invitrogen). Blots were probed using antibodies for DNMT1 (Abcam ab16632).

4.4. Apoptosis Assay

Apoptosis was detected by Annexin-V and propidium iodide (PI) co-staining using the APOAF commercial kit (Sigma, St. Louis, MO, USA). Cells (5 × 10⁵) were washed and incubated for 30 min with FITC-conjugated Annexin-V at room temperature. Cells were then resuspended in binding buffer containing PI and immediately analyzed by flow cytometry.

4.5. RNR Inhibition Assay

The method used to extract and quantitate nucleotides followed previously reported procedures [39]. Prior to extraction, HeLa cells were treated with 50 µM gemcitabine or NUC013 for 16 h.

4.6. NCI 60 Cell Line Panel

Details of the NCI 60 One Dose Screen are well known and available online [40].

4.7. In Vitro Activity

Cells were grown in an appropriate medium for the cell line of interest; 96 well plates of each cell line were seeded with 5000 cells per well and left overnight. Drug exposed cells were incubated at 37 °C for 72 h. At the end of the 72 h exposure period, plates were removed for the CellTiter-Glo® assay. Luminescence was recorded on a Synergy 4.0. Assays were performed in triplicate.

4.8. Pharmacokinetic Study

This study was carried out in strict accordance with the recommendations of the NIH Guide for the Care and Use of Laboratory Animals. The protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of Eurofin Panlabs Taiwan Ltd (AAALAC Accreditation: 001553).

Twenty-four mice were administered 10 mg/kg NUC013 IV, n = 3 animals per timepoint at 8 timepoints (3, 10, 30, 60, 120, 240, 360 and 1440 min) and control animals (n = 3, for drug-free...
blood collection). Blood aliquots (300–400 µL) were collected via cardiac puncture from anesthetized mice in anticoagulant coated tubes, then kept on ice and centrifuged at 2500 × g for 15 min at 4 °C. The plasma was harvested and kept frozen at −80 °C. Plasma samples were processed using acetonitrile precipitation and analyzed by HPLC-MS/MS. A plasma calibration curve was generated and a reportable linear range determined, along with the lower limit of quantitation.

4.9. Tolerability Study

The tolerability study and the tumor xenograft studies (below) were performed at the same institution. These studies were carried out in strict accordance with the recommendations of the NIH Guide for the Care and Use of Laboratory Animals. The protocols were approved by the IACUC of Southern Research Institute (Birmingham, AL, USA) (AAALAC Accreditation: 000643).

Three mice were placed in a dose group on the first day of treatment (Day 1). Animals were treated with the selected dose of NUC013 administered intravenously for 3 consecutive days a week for 3 weeks. Animals were observed daily for mortality and moribundity. Body weights were measured daily starting on day 1. Animals were observed for up to 14 days after the last day of treatment. The MTD was determined by the highest dose at which animals did not die or were not euthanized and had less than 10% weight loss from the start of the study.

4.10. Tumor Xenograft Studies

First, 10⁷ tumor cells from culture in Matrigel™ of HL-60 human leukemia or LoVo colon cancer were implanted subcutaneously in the flank of 1.75-fold the number of NCr-nu/nu mice required for the study. Study initiation began when the required number of mice had tumors of approximately:

- 100 to 250 mm³ (target group mean tumor volume of approximately 175 mm³) for the first set of studies.
- 14 to 63 mm³ (target group mean tumor weight of approximately 30 mm³) for the second set of studies.

Mice with tumors in the proper volume range were arbitrarily assigned to groups. Mice received test article on 3 consecutive days per week for 3 weeks. Mice were observed daily for mortality and moribundity with weights and the tumor measurements taken twice weekly. Tumor volume was determined using the formula for an ellipsoid sphere: Length × Width²/2 = Volume (mm³). The experiments were scheduled to last for 60 days from the day of tumor implant. Any animal whose weight decreased more than 30% from the weight on the first day of treatment or whose tumor reached 4000 mm³ in volume, ulcerated or sloughed off, or was moribund was euthanized prior to study termination.

5. Conclusions

NUC013 has been shown to be a DNA methyl transferase inhibitor and an inhibitor of ribonucleotide reductase. In the NCI 60 cell line panel, NUC013 has demonstrated activity against significantly more cell lines than decitabine, particularly against TP53 WT cell lines. The effectiveness of NUC013 against TP53 WT cell lines may be mediated, at least in part, by derepression of TP53 and inhibition of p53R2 thus facilitating incorporation of NUC013 through self-potentiation. In animal models of human leukemia (TP53 null) and human colon cancer (TP53 WT), NUC013 has been shown to be significantly safer and more effective than decitabine at the tested doses and schedules.

Supplementary Materials: The following are available online at www.mdpi.com/1424-8247/10/3/65/s1, Table S1: Comparison of growth inhibitory activity of decitabine and NUC013 in NCI 60 Cell Line Panel. Activity of NUC013 was only measured at 10 µM. Growth of <50% implies that the GI₅₀ is <10⁻⁵ M and, conversely, growth ≥50% that the GI₅₀ is ≥10⁻⁵ M. Cells in the table were shaded in yellow for GI₅₀ ≥10⁻⁵ M or growth ≥50%, and in green if GI₅₀ < 10⁻⁵ M or growth <50%, Figure S1: (A) Comparison of growth inhibition of p53 WT colon cancer cell line LoVo by decitabine and NUC013. Decitabine GI₅₀ > 50 µM and NUC013 = 3.0 µM. (B) Comparison of
growth inhibition of p53 WT colon cancer cell line Ls174T by decitabine and NUC013. Decitabine IC50 > 50 µM and NUC013 = 1.3 µM, Figure S2: Mean concentration-time profile of NUC013 after IV administration in mice.

Acknowledgments: Research was funded in part by a grant from the Life Sciences Discovery Fund (Seattle, WA, USA) and by AmorChem (Montreal, QC, Canada). This research would not have been possible without the contribution of many scientists. D. Sergueev was responsible for the original synthesis of NUC013 and D. Kessler’s group characterized the original biology at Sonus Pharmaceuticals. Screening of NUC013 for activity by the NCI has also been critical to the compound’s success. Since then, work has been performed by scientists and their teams at a number of contract research organizations including: D. Guay at NuChem, L. Balakireva at Novocib, C.C. Shen, D. Axworthy and W.C. Tseng at Eurofin Panlabs Taiwan, M. Koratich and M. Stackhouse at Southern Research Institute. Finally, I would like to thank B. Clary for proofreading and editorial comments.

Author Contributions: Richard Daifuku is the inventor of NUC013, conceived and designed the experiments, analyzed the data and wrote the paper. Zhenbo Hu and Yogen Saunthararajah contributed the data on THP-1 and Kasumi-1.

Conflicts of Interest: Richard Daifuku is sole partner of Epigenetics Pharma, LLC. The funding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

References
1. Kazanets, A.; Shorstova, T.; Hilmi, K.; Marques, M.; Witcher, M. Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential. Biochim. Biophys. Acta 2016, 1865, 275–288. [PubMed]
2. Momparler, R.L. Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine). Semin Oncol. 2005, 32, 443–451. [CrossRef] [PubMed]
3. The European Medicines Agency. Dacogen (Decitabine). 2016. Available online: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002221/human_med_001589.jsp&mid=WCIb01ac058001d124 (accessed on 16 July 2017).
4. Sorm, F.; Piskala, A.; Cihák, A.; Veselý, J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia 1964, 20, 202–203. [CrossRef] [PubMed]
5. Pliml, J.; Sorm, F. Synthesis of 2′-deoxy-d-ribofuranosyl-5azacytosine. Collect. Czech. Chem. Commun. 1964, 29, 2576–2577. [CrossRef]
6. Bouchard, J.; Momparler, R.L. Incorporation of 5-Aza-2′-deoxycytidine-5′-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase. Mol. Pharmacol. 1983, 24, 109–114. [PubMed]
7. Cellgene Corporation. Highlights of Prescribing Information. Vidaza (Azacitidine for Injection), 2016. Available online: http://www.cellgene.com/content/uploads/vidaza-pi.pdf (accessed on 16 July 2017).
8. Otsuka America Pharmaceutical Inc. Highlights of Prescribing Information. Dacogen® (Decitabine) for Injection. 2014. Available online: http://www.dacogen.com/HCP/Index.aspx (accessed on 16 July 2017).
9. Issa, J.-P. DNA methylation as a therapeutic target in cancer. Clin. Cancer Res. 2007, 13, 1634–1637. [CrossRef] [PubMed]
10. Voytek, P.; Beisier, J.A.; Abbasi, M.M.; Wolpert-DeFilippes, M.K. Comparative studies of the cytostatic action and metabolism of 5-azacytidine and 5,6-dihydro-5-azacytidine. Cancer Res. 1977, 37, 1956–1961. [PubMed]
11. Eli Lilly and Company. Highlights of Prescribing Information, Gemzar (Gemcitabine for Injection). Available online: http://pi.lilly.com/us/gemzar.pdf (accessed on 16 July 2017).
12. Leroy, B.; Girard, L.; Hollestelle, A.; Minna, J.D.; Gazdar, A.F.; Soussi, T. Analysis of TP53 mutation status in human cancer cell lines: A reassessment. Hum. Mutat. 2014, 35, 756–765. [CrossRef] [PubMed]
13. Christman, J.K. 5-azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implication for cancer therapy. Oncogene 2002, 21, 5483–5495. [CrossRef] [PubMed]
14. Wang, J.; Lohman, G.J.; Stubbe, J. Enhanced subunit interactions with gemcitabine-5′-diphosphate inhibit ribonucleotide reductases. Proc. Natl. Acad. Sci. USA 2007, 104, 14324–14329. [CrossRef] [PubMed]
15. Wang, J.; Lohman, G.J.; Stubbe, J.A. Mechanism of inactivation of human ribonucleotide reductase with p53R2 by gemcitabine 5′-diphosphate. Biochemistry 2009, 48, 11612–11621. [CrossRef] [PubMed]
16. Zielinski, W.S.; Sprinzl, M. Chemical synthesis of 5-azacytidine nucleotides and preparation of tRNAs containing 5-azacytidine in its 3′-terminus. Nucleic Acids Res. 1984, 12, 5025–5036. [CrossRef] [PubMed]
17. Piall, E.M.; Aherne, G.W.; Marks, V. The quantitative determination of 2′-deoxycytidine-5′-triphosphate in cell extracts by radioimmunoassay. Anal. Biochem. 1986, 154, 276–281. [CrossRef]
18. Bianchi, V.; Pontis, E.; Reichard, P. Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J. Biol. Chem. 1986, 261, 16037–16042. [PubMed]

19. Novocib. Cellular Assay for RNR Inhibitors. 2014. Available online: http://www.novocib.com/RNR_Inhibition_Whole_Cell_Screening.html (accessed on 16 July 2017).

20. Chen, P.; Liu, Z.; Liu, S.; Xie, Z.; Aimiuwu, J.; Pang, J.; Klisovic, R.; Blum, W.; Grever, M.R.; Marcucci, G.; et al. A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels. Pharm. Res. 2009, 26, 1504–1515. [CrossRef] [PubMed]

21. Link, P.A.; Baer, M.R.; James, S.R.; Jones, D.A.; Karpf, A.R. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res. 2008, 68, 9358–9366. [CrossRef] [PubMed]

22. Yousefi, B.; Samadi, N.; Ahmadi, Y. Akt and p53R2, partners that dictate the progression and invasiveness of cancer. DNA Repair 2014, 22, 24–29. [CrossRef] [PubMed]

23. Qi, J.J.; Liu, L.; Cao, J.X.; An, G.S.; Li, S.Y.; Li, G.; Jia, H.T.; Ni, J.H. E2F1 regulates p53R2 gene expression in p53-deficient cells. Mol. Cell. Biochem. 2015, 399, 179–188. [CrossRef] [PubMed]

24. Matsushita, S.; Ikeda, R.; Fukushige, T.; Tajitsu, Y.; Gunshin, K.; Okumura, H.; Usuiyama, M.; Akiyama, S.; Kawai, K.; Takeda, Y.; et al. p53R2 is a prognostic factor of melanoma and regulates proliferation and chemosensitivity of melanoma cells. J. Dermatol. Sci. 2012, 68, 19–24. [CrossRef] [PubMed]

25. Pontarin, G.; Ferraro, P.; Bee, L.; Reichard, P.; Bianchi, V. Mammalian ribonucleotide reductase subunit p53R2 is required for mitochondrial DNA replication and DNA repair in quiescent cells. Proc. Natl. Acad. Sci. USA 2012, 109, 13302–13307. [CrossRef] [PubMed]

26. Momparler, R.L. Pharmacology of 5-Aza-2′-deoxycytidine (decitabine). Semin. Hematol. 2005, 42, S9–S16. [CrossRef] [PubMed]

27. Al-Salihi, M.; Yu, M.; Burnett, D.M.; Alexander, A.; Samlowski, W.E.; Fitzpatrick, F.A. The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2′-deoxycytidine (decitabine) are differentially regulated by cell cycle progression. Epigenetics 2011, 6, 1021–1028. [CrossRef] [PubMed]

28. Mini, E.; Nobili, S.; Caciagli, B.; Landini, I.; Mazzei, T. Cellular pharmacology of gemcitabine. Ann. Oncol. 2006, 17, v7–v12. [CrossRef] [PubMed]

29. Zhu, W.G.; Hileman, T.; Ke, Y.; Wang, P.; Lu, S.; Duan, W.; Dai, Z.; Tong, T.; Villalona-Calero, M.A.; Plass, C.; et al. 5-aza-2′-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J. Biol. Chem. 2004, 279, 15161–15166. [CrossRef] [PubMed]

30. Zhang, Q.; Zeng, S.X.; Lu, H. Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell. Biochem. 2014, 85, 281–319. [PubMed]

31. Nieto, M.; Samper, E.; Fraga, M.F.; González de Buitrago, G.; Esteller, M.; Serrano, M. The absence of p53 is critical for the induction of apoptosis by 5-aza-2′-deoxycytidine. Oncogene 2004, 23, 735–743. [CrossRef] [PubMed]

32. Leonova, K.I.; Brodsky, L.; Lipchick, B.; Pal, M.; Novototskaya, L.; Chenchik, A.A.; Sen, G.C.; Komarova, E.A.; Gudkov, A.V.; et al. p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc. Natl. Acad. Sci. USA 2013, 110, E89–E98. [CrossRef] [PubMed]

33. Yi, L.; Sun, Y.; Levine, A. Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells. Oncotarget 2014, 5, 8924–8936. [CrossRef] [PubMed]

34. Fandy, T.E.; Jiemjit, A.; Thakar, M.; Rhoden, P.; Suarez, L.; Gore, S.D. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes. Clin. Cancer Res. 2014, 20, 1249–1258. [CrossRef] [PubMed]

35. Van Camp, J.A. Decitabine (Dacogen), A DNA methyltransferase inhibitor for cancer. In Modern Drug Synthesis; Li, J.J., Johnson, D.S., Eds.; Wiley: Hoboken, NJ, USA, 2010.

36. Mahfouz, R.Z.; Jankowska, A.; Elbraham, Q.; Gu, X.; Visconte, V.; Tabarroki, A.; Terse, P.; Covey, J.; Chan, K.; Ling, Y.; et al. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin. Cancer Res. 2013, 19, 938–948. [CrossRef] [PubMed]
37. Serdjebi, C.; Seitz, J.F.; Ciccolini, J.; Duluc, M.; Norguet, E.; Fina, F.; Lacarelle, B.; Ouafik, L.; Dahan, L. Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen. *Pharmacogenomics* **2013**, *14*, 1047–1051. [CrossRef] [PubMed]

38. Epigentek Group Inc. EpiQuik™ DNA Methyltransferase Activity/Inhibition Assay Kit. 2014. Available online: [https://www.epigentek.com/docs/P-3001.pdf](https://www.epigentek.com/docs/P-3001.pdf) (accessed on 16 July 2017).

39. Novocib. RNR Inhibition—Whole Cell Assay. Available online: [http://www.novocib.com/images/NovoCIB%20WCS-Nov6.pdf](http://www.novocib.com/images/NovoCIB%20WCS-Nov6.pdf) (accessed on 16 July 2017).

40. National Cancer Institute. Developmental Therapeutics Program. NCI 60 Screening Methodology, 2015. Available online: [https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm](https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm) (accessed on 16 July 2017).